Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient

E. Cofrancesco, C. Boschetti, M. A. Viviani, C. Bargiggia, A. M. Tortorano, M. Cortellaro, C. Zanussi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We recently succeeded in eradicating a Fusarium infection by treatment with liposomal amphotericin B (L-AmB). The patient, a 22-year-old man with acute lymphoblast leukaemia (ALL), developed fever and diffuse cutaneous maculopapular necrotising nodules during post-chemotherapy neutropenia. Fusarium verticilloides was isolated from the skin, and hyphae were observed on direct microscopy. Despite increased WBC and amphotericin B (AmB) treatment (0.7 mg/kg/day for 11 days), he remained febrile and a chest X-ray revealed pulmonary lesions. Fusarium infection was confirmed by bronchial aspirate. AmB was increased to 1 mg/kg/day, and continued for 16 days (total dose 1630 mg). A slight improvement was observed at tomography, but nephrotoxicity developed. Treatment was changed to L-AmB (3 mg/kg/day). The patient received this drug for 20 days (total dose of 3850 mg) with complete regression of the pulmonary lesions. No adverse event occurred, and nephrotoxicity resolved. The patient was discharged from hospital cured of the Fusarium infection and in clinical and haematological remission. No relapse of fusariosis occurred, despite additional courses of intensive chemotherapy. Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
JournalHaematologica
Volume77
Issue number3
Publication statusPublished - 1992

Fingerprint

Fusariosis
Amphotericin B
Fever
Therapeutics
Drug Therapy
Lung
Skin
Hyphae
Mycoses
Fusarium
Neutropenia
liposomal amphotericin B
Microscopy
Leukemia
Thorax
Tomography
X-Rays
Kidney
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Cofrancesco, E., Boschetti, C., Viviani, M. A., Bargiggia, C., Tortorano, A. M., Cortellaro, M., & Zanussi, C. (1992). Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient. Haematologica, 77(3), 280-283.

Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient. / Cofrancesco, E.; Boschetti, C.; Viviani, M. A.; Bargiggia, C.; Tortorano, A. M.; Cortellaro, M.; Zanussi, C.

In: Haematologica, Vol. 77, No. 3, 1992, p. 280-283.

Research output: Contribution to journalArticle

Cofrancesco, E, Boschetti, C, Viviani, MA, Bargiggia, C, Tortorano, AM, Cortellaro, M & Zanussi, C 1992, 'Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient', Haematologica, vol. 77, no. 3, pp. 280-283.
Cofrancesco E, Boschetti C, Viviani MA, Bargiggia C, Tortorano AM, Cortellaro M et al. Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient. Haematologica. 1992;77(3):280-283.
Cofrancesco, E. ; Boschetti, C. ; Viviani, M. A. ; Bargiggia, C. ; Tortorano, A. M. ; Cortellaro, M. ; Zanussi, C. / Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient. In: Haematologica. 1992 ; Vol. 77, No. 3. pp. 280-283.
@article{5c92690bd9684d588198c02d8427a581,
title = "Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient",
abstract = "We recently succeeded in eradicating a Fusarium infection by treatment with liposomal amphotericin B (L-AmB). The patient, a 22-year-old man with acute lymphoblast leukaemia (ALL), developed fever and diffuse cutaneous maculopapular necrotising nodules during post-chemotherapy neutropenia. Fusarium verticilloides was isolated from the skin, and hyphae were observed on direct microscopy. Despite increased WBC and amphotericin B (AmB) treatment (0.7 mg/kg/day for 11 days), he remained febrile and a chest X-ray revealed pulmonary lesions. Fusarium infection was confirmed by bronchial aspirate. AmB was increased to 1 mg/kg/day, and continued for 16 days (total dose 1630 mg). A slight improvement was observed at tomography, but nephrotoxicity developed. Treatment was changed to L-AmB (3 mg/kg/day). The patient received this drug for 20 days (total dose of 3850 mg) with complete regression of the pulmonary lesions. No adverse event occurred, and nephrotoxicity resolved. The patient was discharged from hospital cured of the Fusarium infection and in clinical and haematological remission. No relapse of fusariosis occurred, despite additional courses of intensive chemotherapy. Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity.",
author = "E. Cofrancesco and C. Boschetti and Viviani, {M. A.} and C. Bargiggia and Tortorano, {A. M.} and M. Cortellaro and C. Zanussi",
year = "1992",
language = "English",
volume = "77",
pages = "280--283",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient

AU - Cofrancesco, E.

AU - Boschetti, C.

AU - Viviani, M. A.

AU - Bargiggia, C.

AU - Tortorano, A. M.

AU - Cortellaro, M.

AU - Zanussi, C.

PY - 1992

Y1 - 1992

N2 - We recently succeeded in eradicating a Fusarium infection by treatment with liposomal amphotericin B (L-AmB). The patient, a 22-year-old man with acute lymphoblast leukaemia (ALL), developed fever and diffuse cutaneous maculopapular necrotising nodules during post-chemotherapy neutropenia. Fusarium verticilloides was isolated from the skin, and hyphae were observed on direct microscopy. Despite increased WBC and amphotericin B (AmB) treatment (0.7 mg/kg/day for 11 days), he remained febrile and a chest X-ray revealed pulmonary lesions. Fusarium infection was confirmed by bronchial aspirate. AmB was increased to 1 mg/kg/day, and continued for 16 days (total dose 1630 mg). A slight improvement was observed at tomography, but nephrotoxicity developed. Treatment was changed to L-AmB (3 mg/kg/day). The patient received this drug for 20 days (total dose of 3850 mg) with complete regression of the pulmonary lesions. No adverse event occurred, and nephrotoxicity resolved. The patient was discharged from hospital cured of the Fusarium infection and in clinical and haematological remission. No relapse of fusariosis occurred, despite additional courses of intensive chemotherapy. Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity.

AB - We recently succeeded in eradicating a Fusarium infection by treatment with liposomal amphotericin B (L-AmB). The patient, a 22-year-old man with acute lymphoblast leukaemia (ALL), developed fever and diffuse cutaneous maculopapular necrotising nodules during post-chemotherapy neutropenia. Fusarium verticilloides was isolated from the skin, and hyphae were observed on direct microscopy. Despite increased WBC and amphotericin B (AmB) treatment (0.7 mg/kg/day for 11 days), he remained febrile and a chest X-ray revealed pulmonary lesions. Fusarium infection was confirmed by bronchial aspirate. AmB was increased to 1 mg/kg/day, and continued for 16 days (total dose 1630 mg). A slight improvement was observed at tomography, but nephrotoxicity developed. Treatment was changed to L-AmB (3 mg/kg/day). The patient received this drug for 20 days (total dose of 3850 mg) with complete regression of the pulmonary lesions. No adverse event occurred, and nephrotoxicity resolved. The patient was discharged from hospital cured of the Fusarium infection and in clinical and haematological remission. No relapse of fusariosis occurred, despite additional courses of intensive chemotherapy. Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0026647959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026647959&partnerID=8YFLogxK

M3 - Article

C2 - 1427436

AN - SCOPUS:0026647959

VL - 77

SP - 280

EP - 283

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -